Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01037205 · ClinicalTrials.gov registry record · Phase 2
Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza
A Phase 2 study, sponsored by Ansun Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
NCT01037205 is a Phase 2 study that has completed, run by Ansun Biopharma. The registered enrollment target is 264 participants.
The verdict
NCT01037205, a Phase 2 study, has completed, sponsored by Ansun Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
Study Summary
This protocol will seek to enroll adult otherwise healthy subjects presenting with influenza-like illness (ILI). Subjects will enter the study based on listed inclusion/exclusion criteria, including a positive diagnostic test for influenza virus (IFV).
Interventions
- DRUG DAS181 dry powder, formulation F02
- DRUG Respitose ML006 (DMV-Fonterra)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01037205
The ClinicalTrials.gov registry entry for NCT01037205 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ansun Biopharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DAS181 dry powder, formulation F02 is the first listed.
NCT01037205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01037205 about?
NCT01037205 is a clinical study titled "Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza". This protocol will seek to enroll adult otherwise healthy subjects presenting with influenza-like illness (ILI). Subjects will enter the study based on listed inclusion/exclusion criteria, including a positive diagnostic test for influenza virus (IFV).
What is the current status of trial NCT01037205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2009-12. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01037205?
The interventions under investigation include: DAS181 dry powder, formulation F02 (DRUG), Respitose ML006 (DMV-Fonterra) (DRUG).
Who is sponsoring clinical trial NCT01037205?
This trial is sponsored by Ansun Biopharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.